What do we mean by sensitivity when we talk about detecting minimal residual disease?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Leukemia

• Publication date

  2008-02-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2008.33PMID 18305558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

  2007cited by this paper
• High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

  2006cited by this paper
• Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia

  2006cited by this paper
• Minimal residual disease studies in acute leukemia.

  2004cited by this paper
• Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.

  2003cited by this paper
• Minimal residual disease evaluation in acute myeloid leukaemia.

  2002cited by this paper
• Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia

  2001cited by this paper
• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

  2001cited by this paper
• Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

  2000cited by this paper
• Mutations and promoter methylation status of NPM1 in myeloproliferative disorders

  1996cited by this paper

• Circulating Tumor DNA in Pediatric Cancer

  2022cites this paper
• Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature.

  2020cites this paper
• Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

  2016cites this paper
• Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

  2015cites this paper
• Surface Enhanced Raman Spectroscopy-Based Method for Leukemia Biomarker Detection Using Magnetic Core @ Gold Shell Nanoparticles

  2014cites this paper
• Polymer nanopillar-gold arrays as surface-enhanced Raman spectroscopy substrate for the simultaneous detection of multiple genes.

  2014cites this paper
• Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

  2014cites this paper
• Bifunctional nanoparticles for surface-enhanced Raman spectroscopy-based leukemia biomarker detection

  2014cites this paper
• Minimal residual disease in acute myeloid leukemia: coming of age.

  2012cites this paper
• Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis

  2010cites this paper
• Reply to Ross et al.

  2009cites this paper
• Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin

  2009cites this paper
• Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study

  2009cites this paper